
Sign up to save your podcasts
Or


In this Business Breakdown, David Barbato and Christian Schmidt sit down with Iridex’s (NASDAQ: IRIX) CEO Patrick Mercer and CFO Romeo Dizon. The company was originally profiled by member “jbhw28” on December 17, 2013, at $8.64 USD per share.
This discussion took place live on February 27th, 2026, on the MicroCapClub Community. Join MicroCapClub and unlock the ability to listen and participate live in these discussions - https://microcapclub.com/join-now/
This comprehensive interview with Patrick Mercer and Romeo Dizon of Iridex covers the company's strategic focus, financial turnaround, product portfolio, market opportunities, and future plans. Gain insights into how Iridex is positioning itself for growth in ophthalmic laser technology and the healthcare industry.
✉️ Share your feedback - [email protected]
✉️ David’s X (Twitter) - https://x.com/Valuehunte
Chapters
00:00 Introduction and Professional Backgrounds
04:57 Business Performance and Financial Overview
11:09 Retina Products and Market Opportunities
14:06 Glaucoma Treatment Innovations and Market Potential
19:34 Sales Strategy and Financial Health
22:02 Q&A: Addressing Profitability Concerns
26:25 Reimbursement Environment and Its Impact
28:59 Socioeconomic Considerations in Glaucoma Treatment
30:21 Drivers of Revenue Growth
32:43 Future Acquisition Plans and Strategic Moves
37:03 Understanding Cash Injection and Equity Alternatives
37:45 Exploring the Relationship with Novel
38:49 Competitive Landscape and Pricing Strategies
40:43 Sales Force Efficiency and Company Strategy
42:48 Evaluating Future Sales Force Expansion
43:40 Operational Changes and Cost Management
47:41 Headquarters Relocation and Employee Impact
49:41 Prioritizing Cost Savings and Operational Efficiency
52:46 CEO Adaptation and Investor Relations
55:49 Future Outlook and Accountability Metrics
Disclaimer: All content on this channel is for discussion, education, entertainment, and illustrative purposes only and SHOULD NOT be construed as professional financial advice, solicitation, or recommendation to buy or sell any securities, notwithstanding anything stated on this channel. There are risks associated with investing in securities. Loss of principal is possible. Past performance is not a predictor of future investment performance. Ian Cassel and the guests on this channel are not responsible for investment actions taken by viewers. Should you need such advice, consult a licensed financial advisor, legal advisor, or tax advisor. You agree to verify all information yourself before investing. Any past performance discussed during this program is no guarantee of future results. Investing involves risk and possible loss of principal capital; please seek advice from a licensed professional. All views expressed are personal opinions as of the date of recording and are subject to change without the responsibility to update views. No guarantee is given regarding the accuracy of the information on this channel. Releasees undertake no obligation to provide accurate or sound investment statements. You waive any and all duties that may exist flowing from you to any Releasee. You agree not to hold any Releasee liable for any possible claim for damages arising from any decision you make based on information or other content on the Channel.
By MicroCapClub4.8
1616 ratings
In this Business Breakdown, David Barbato and Christian Schmidt sit down with Iridex’s (NASDAQ: IRIX) CEO Patrick Mercer and CFO Romeo Dizon. The company was originally profiled by member “jbhw28” on December 17, 2013, at $8.64 USD per share.
This discussion took place live on February 27th, 2026, on the MicroCapClub Community. Join MicroCapClub and unlock the ability to listen and participate live in these discussions - https://microcapclub.com/join-now/
This comprehensive interview with Patrick Mercer and Romeo Dizon of Iridex covers the company's strategic focus, financial turnaround, product portfolio, market opportunities, and future plans. Gain insights into how Iridex is positioning itself for growth in ophthalmic laser technology and the healthcare industry.
✉️ Share your feedback - [email protected]
✉️ David’s X (Twitter) - https://x.com/Valuehunte
Chapters
00:00 Introduction and Professional Backgrounds
04:57 Business Performance and Financial Overview
11:09 Retina Products and Market Opportunities
14:06 Glaucoma Treatment Innovations and Market Potential
19:34 Sales Strategy and Financial Health
22:02 Q&A: Addressing Profitability Concerns
26:25 Reimbursement Environment and Its Impact
28:59 Socioeconomic Considerations in Glaucoma Treatment
30:21 Drivers of Revenue Growth
32:43 Future Acquisition Plans and Strategic Moves
37:03 Understanding Cash Injection and Equity Alternatives
37:45 Exploring the Relationship with Novel
38:49 Competitive Landscape and Pricing Strategies
40:43 Sales Force Efficiency and Company Strategy
42:48 Evaluating Future Sales Force Expansion
43:40 Operational Changes and Cost Management
47:41 Headquarters Relocation and Employee Impact
49:41 Prioritizing Cost Savings and Operational Efficiency
52:46 CEO Adaptation and Investor Relations
55:49 Future Outlook and Accountability Metrics
Disclaimer: All content on this channel is for discussion, education, entertainment, and illustrative purposes only and SHOULD NOT be construed as professional financial advice, solicitation, or recommendation to buy or sell any securities, notwithstanding anything stated on this channel. There are risks associated with investing in securities. Loss of principal is possible. Past performance is not a predictor of future investment performance. Ian Cassel and the guests on this channel are not responsible for investment actions taken by viewers. Should you need such advice, consult a licensed financial advisor, legal advisor, or tax advisor. You agree to verify all information yourself before investing. Any past performance discussed during this program is no guarantee of future results. Investing involves risk and possible loss of principal capital; please seek advice from a licensed professional. All views expressed are personal opinions as of the date of recording and are subject to change without the responsibility to update views. No guarantee is given regarding the accuracy of the information on this channel. Releasees undertake no obligation to provide accurate or sound investment statements. You waive any and all duties that may exist flowing from you to any Releasee. You agree not to hold any Releasee liable for any possible claim for damages arising from any decision you make based on information or other content on the Channel.

3,371 Listeners

1,983 Listeners

82 Listeners

2,349 Listeners

944 Listeners

797 Listeners

362 Listeners

295 Listeners

202 Listeners

558 Listeners

86 Listeners

354 Listeners

167 Listeners

277 Listeners

154 Listeners